20 / 35
Page 84
Volume 08
Clinical Pharmacology & Biopharmaceutics
ISSN: 2167-065X
Pharmacology 2019
World Heart Congress 2019
August 19-20, 2019
JOINT EVENT
conferenceseries
.com
August 19-20, 2019 Vienna, Austria
&
7
th
World Heart Congress
24
th
World Congress on
Pharmacology
Prenatal MR imaging of congenital heart diseases and associated abnormalities
Tamara Feygin
Perelman Medical School at University of Pennsylvania, USA
The Children’s Hospital of Philadelphia, USA
A
variety of congenital heart diseases (CHD) may be diagnosed prenatally. Traditionally, the fetal heart was
primarily assessed by fetal echography. However, fetal MRI has been proven as a helpful imaging tool in detection
of cardio-vascular anomalies in utero. Numerous conditions, including aorta coarctation, hypoplastic left heart
syndrome, tetralogy of Fallout, cardiac aneurysm, pericardial/cardiac tumors may be demonstrated on MR imaging.
In addition, presence of other coexisting anomalies outside of the cardio-vascular system may be discovered. Some
cardio-vascular anomalies may be more than an isolated problem and could be a part of an underlying systemic/
genetic condition. Even in the absence of genetic abnormalities, infants with CHD are at increased risk of brain
lesions (15-45%) or neurodevelopmental delay. The demonstration of a full spectrum of fetal anomalies provides
extremely valuable information to clinicians and parents-to be. Fetal MR may be a feasible addition for timely and
precise diagnosis of cardiac disease and associated anomalies. Prenatal imaging therefore helps to predict pregnancy
outcome, and prepares couples for the birth of a child with an abnormality. The obtained information may also assist
in thorough screening of fetal patients for eligibility for fetal treatment. It may help to prognosticate to some degree
important issues of patient’s developmental outcome and quality of life.
Clin Pharmacol Biopharm, Volume 08